Ipsen (FR:IPN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ipsen has expanded its oncology research partnership with Marengo Therapeutics to include new preclinical development collaborations for ‘T-Cell Engager’ assets via Marengo’s TriSTAR platform. These efforts aim to activate T lymphocytes against ‘cold’ tumors, which are challenging to treat with traditional therapies. The agreement includes an initial payment to Marengo with potential milestone payments totaling up to $1.2 billion, plus tiered royalties on global sales.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.